• About
  • Policies
  • What is open access
  • Library
  • Contact
Advanced search
      View Item 
      •   BUIR Home
      • Scholarly Publications
      • Institute of Materials Science and Nanotechnology (UNAM)
      • View Item
      •   BUIR Home
      • Scholarly Publications
      • Institute of Materials Science and Nanotechnology (UNAM)
      • View Item
      JavaScript is disabled for your browser. Some features of this site may not work without it.

      A highly potent SARS-CoV-2 blocking lectin protein

      Thumbnail
      View / Download
      8.1 Mb
      Author(s)
      Ahan, Recep E.
      Hanifehnezhad, A.
      Kehribar, Ebru Ş.
      Oguzoglu, T. C.
      Földes, K.
      Özçelik, Cemile E.
      Filazi, N.
      Öztop, S.
      Palaz, F.
      Önder, S.
      Bozkurt, Eray U.
      Ergünay, K.
      Özkul, A.
      Şeker, Urartu Özgür Şafak
      Date
      2022-04-15
      Source Title
      ACS Infectious Diseases
      Print ISSN
      23738227
      Electronic ISSN
      2373-8227
      Publisher
      American Chemical Society
      Volume
      8
      Issue
      7
      Pages
      1253 - 1264
      Language
      English
      Type
      Article
      Item Usage Stats
      16
      views
      8
      downloads
      Abstract
      The COVID-19 (coronavirus disease-19) pandemic affected more than 180 million people around the globe, causing more than five million deaths as of January 2022. SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the new coronavirus, has been identified as the primary cause of the infection. The number of vaccinated people is increasing; however, prophylactic drugs are highly demanded to ensure secure social contact. A number of drug molecules have been repurposed to fight against SARS-CoV-2, and some of them have been proven to be effective in preventing hospitalization or ICU admissions. Here, we demonstrated griffithsin (GRFT), a lectin protein, to block the entry of SARS-CoV-2 and its variants, Delta and Omicron, into the Vero E6 cell lines and IFNAR-/-mouse models by attaching to the spike protein of SARS-CoV-2. Given the current mutation frequency of SARS-CoV-2, we believe that GRFT protein-based drugs will have a high impact in preventing the transmission of both the Wuhan strain as well as any other emerging variants, including Delta and Omicron variants, causing the high-speed spread of COVID-19.
      Permalink
      http://hdl.handle.net/11693/111255
      Published Version (Please cite this version)
      https://dx.doi.org/10.1021/acsinfecdis.2c00006
      Collections
      • Institute of Materials Science and Nanotechnology (UNAM) 2258
      Show full item record

      Browse

      All of BUIRCommunities & CollectionsTitlesAuthorsAdvisorsBy Issue DateKeywordsTypeDepartmentsCoursesThis CollectionTitlesAuthorsAdvisorsBy Issue DateKeywordsTypeDepartmentsCourses

      My Account

      Login

      Statistics

      View Usage StatisticsView Google Analytics Statistics

      Bilkent University

      If you have trouble accessing this page and need to request an alternate format, contact the site administrator. Phone: (312) 290 2976
      © Bilkent University - Library IT

      Contact Us | Send Feedback | Off-Campus Access | Admin | Privacy